Intra-Cellular Therapies, Inc., announced additional preclinical data from its ongoing development
programs for ITI-007, the Company’s first-in-class dual 5HT2A receptor
antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722,
a low-dose formulation of ITI-007, which are in development for
schizophrenia and sleep disorders, respectively. These new data demonstrate
ITI-007 (more…)
Aspect Medical Systems, Inc. (NASDAQ: ASPM) will present study results from the BRITE (Biomarkers for Rapid Identification of Treatment Effectiveness) trial in major depression at the Society of Biological Psychiatry and American Psychiatric Association Annual Meetings in Washington D.C. this week. (more…)
A new revision of clinical guidelines to help doctors manage patients with depression has challenged the rationale behind the UK government’s policy of rolling out of cognitive behavioural therapy (CBT) for milder depression.
According to a comprehensive review of treatments for depression, there is a lack of evidence for CBT being more helpful than other forms of psychological (more…)
Nearly one in five, or about 300,000, soldiers who has served in Iraq or Afghanistan has post-traumatic stress disorder or major depression — illnesses that could cost the U.S. as much as $6.2 billion over two years in care, lost productivity and lost lives through suicide, according to a RAND report released on Thursday, the Washington Post reports (Scott Tyson, Washington Post, 4/18). The study was based on telephone interviews conducted (more…)
A paper by Giovanni A. Fava and associates of the University of Bologna published in the April issue of Psychotherapy and Psychosomatics summarizes the evidence which supports the seriousness of agoraphobia as an invalidating disease. At the same time it questions the excessive emphasis on panic which has been attributed in the past decade and the (more…)
A single antidepressant tablet makes a depressed person see the world in a more positive light just four hours after swallowing it, a new study has shown.
Dr Philip Cowen, professor of pharmacology at the Department of Psychiatry at the University of Oxford, told delegates at the Royal College of Psychiatrists’ Annual Meeting (more…)